|
81
|
296
|
2iw6A |
Structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor |
|
80
|
297
|
2i40A |
Cdk2/cyclin a complexed with a thiophene carboxamide inhibitor |
|
85
|
299
|
2g9xA |
Structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor nu6271 |
|
82
|
298
|
2fvdA |
Cyclin dependent kinase 2 (cdk2) with diaminopyrimidine inhibitor |
|
81
|
298
|
2exmA |
Human cdk2 in complex with isopentenyladenine |
|
69
|
296
|
2eufB |
X-ray structure of human cdk6-vcyclin in complex with the inhibitor pd0332991 |
|
64
|
297
|
2f2cB |
X-ray structure of human cdk6-vcyclinwith the inhibitor aminopurvalanol |
|
74
|
298
|
2ds1A |
Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor |
|
68
|
298
|
2duvA |
Structure of cdk2 with a 3-hydroxychromones |
|
86
|
297
|
2cchA |
The crystal structure of cdk2 cyclin a in complex with a substrate peptide derived from cdc modified with a gamma-linked atp analogue |
|
80
|
292
|
2cjmA |
Mechanism of cdk inhibition by active site phosphorylation: cdk2 y15p t160p in complex with cyclin a structure |
|
77
|
296
|
2c6mA |
Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor |
|
79
|
296
|
2c68A |
Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor |
|
81
|
298
|
2c69A |
Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor |
|
77
|
298
|
2c6kA |
Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor |
|
80
|
296
|
2c5vA |
Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design |
|
78
|
296
|
2c5xA |
Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design |
|
76
|
296
|
2c6oA |
Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor |
|
86
|
296
|
2c6tA |
Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor |
|
85
|
296
|
2c5oA |
Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design |
|
77
|
297
|
2cciA |
Crystal structure of phospho-cdk2 cyclin a in complex with a peptide containing both the substrate and recruitment sites of cdc6 |
|
81
|
298
|
2c6iA |
Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor |
|
80
|
297
|
2c5yA |
Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design |
|
89
|
301
|
2c4gA |
Structure of cdk2-cyclin a with pha-533514 |
|
82
|
298
|
2clxA |
4-arylazo-3,5-diamino-1h-pyrazole cdk inhibitors: sar study, crystal structure in complex with cdk2, selectivity, and cellular effects |
|
80
|
296
|
2c5nA |
Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design |
|
77
|
298
|
2c6lA |
Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor |
|
90
|
302
|
2bpmA |
Structure of cdk2-cyclin a with pha-630529 |
|
71
|
298
|
2btsA |
Structure of cdk2 complexed with pnu-230032 |
|
69
|
298
|
2btrA |
Structure of cdk2 complexed with pnu-198873 |
|
80
|
298
|
2bheA |
Human cyclin dependent protein kinase 2 in complex with the inhibitor 5-bromo-indirubine |
|
76
|
298
|
2bhhA |
Human cyclin dependent protein kinase 2 in complex with the inhibitor 4-hydroxypiperindinesulfonyl-indirubine |
|
91
|
302
|
2bkzA |
Structure of cdk2-cyclin a with pha-404611 |
|
78
|
298
|
2b52A |
Human cyclin dependent kinase 2 (cdk2) complexed with dph-042562 |
|
81
|
298
|
2b53A |
Human cyclin dependent kinase 2 (cdk2) complexed with din-234325 |
|
75
|
298
|
2b54A |
Human cyclin dependent kinase 2 (ckd2)complexed with din-232305 |
|
79
|
298
|
2b55A |
Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole din-101312 |
|
71
|
298
|
2a4lA |
Human cyclin-dependent kinase 2 in complex with roscovitine |
|
78
|
298
|
2a0cX |
Human cdk2 in complex with olomoucine ii, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor |
|
78
|
298
|
1ykrA |
Crystal structure of cdk2 with an aminoimidazo pyridine inhibitor |
|
71
|
298
|
1y91A |
Crystal structure of human cdk2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor |
|
79
|
298
|
1y8yA |
Crystal structure of human cdk2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor |
|
69
|
295
|
1xo2B |
Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin |
|
79
|
298
|
1w0xC |
Crystal structure of human cdk2 in complex with the inhibitor olomoucine. |
|
83
|
298
|
1w98A |
The structural basis of cdk2 activation by cyclin e |
|
85
|
302
|
1vywA |
Structure of cdk2/cyclin a with pnu-292137 |
|
82
|
298
|
1w8cA |
Co-crystal structure of 6-cyclohexylmethoxy-8-isopropyl-9h-purin-2- ylamine and monomeric cdk2 |
|
76
|
298
|
1wccA |
Screening for fragment binding by x-ray crystallography |
|
73
|
298
|
1v1kA |
Cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor |
|
73
|
298
|
1vyzA |
Structure of cdk2 complexed with pnu-181227 |
